Skip to content

PTSD research published in 2024

Page 2 of 5: studies 21 to 40 of 95, newest first. Back to the PTSD overview

Studies

Hallucinations across sensory domains in people with post-traumatic stress disorder and psychosis

Psychiatry Research October 11, 2024 Robert Dudley, Sarah White, Rebecca Miskin et al. 4 citations

Auditory hallucinations are common in people with histories of adversity, possibly indicating a causal relationship. However, hallucinations occur in multiple sensory modalities and the relationship between trauma and hallucinations in other sensory domains is less explored. We examined the occurrence of hallucinatory experiences in different sensory modalities in people with psychosis who also...

Understanding nightmares after traumatic events in Detroit (UNiTED): prospective associations with interpersonal violence and posttraumatic stress disorder symptoms

European Journal of Psychotraumatology October 8, 2024 Anthony N Reffi, Philip Cheng, David A Kalmbach et al.

ABSTRACT Background: Research suggests trauma-related nightmares (TRNs) during the acute aftermath of trauma may contribute to posttraumatic stress disorder (PTSD). However, it is unknown who is most vulnerable to TRNs, which is critical to identify at-risk patients toward whom early nightmare-focused treatments can be targeted to prevent PTSD. Objective: We tested trauma type (interpersonal...

Mechanisms of psilocybin on the treatment of posttraumatic stress disorder

Journal of Psychopharmacology October 3, 2024 Charles Q. Choi, Danica E. Johnson, David C J Chen-Li et al. 11 citations

Posttraumatic stress disorder (PTSD) is a condition that can develop after a traumatic event, causing distressing symptoms, including intrusive re-experiencing symptoms, alterations in mood and cognition, and changes in arousal and reactivity. Few treatment options exist for patients who find conventional psychotherapy and pharmacotherapy to be inaccessible, ineffective, or intolerable. We...

Nightmare frequency is a risk factor for suicidal ideation during the COVID-19 pandemic.

Journal of Sleep Research October 1, 2024 Courtney J Bolstad, Brigitte Holzinger, Serena Scarpelli et al.

The association between nightmare frequency (NMF) and suicidal ideation (SI) is well known, yet the impact of the COVID-19 pandemic on this relation is inconsistent. This study aimed to investigate changes in NMF, SI, and their association during the COVID-19 pandemic. Data were collected in 16 countries using a harmonised questionnaire. The sample included 9328 individuals (4848 women; age...

Efficacy of yoga for posttraumatic stress disorder: A systematic review and meta-analysis of randomized controlled trials.

Psychiatry Research October 1, 2024 Seyed Aria Nejadghaderi, Seyed Ehsan Mousavi, Asra Fazlollahi et al. 11 citations

Yoga is an increasingly popular complementary intervention to reduce posttraumatic stress disorder (PTSD) symptoms and related comorbidities, but its safety and treatment efficacy are not firmly established. We conducted a systematic review and meta-analysis of existing randomized control trials (RCTs) of yoga interventions for PTSD and related secondary outcomes (e.g., depression). Initial...

Trait Mindfulness Moderates Treatment Outcomes in a Randomized Controlled Trial of Mantram Repetition Program for Veterans with Post-Traumatic Stress Disorder.

Journal of Integrative and Complementary Medicine October 1, 2024 Skylar Kelsven, Caitlin L Mclean, Kiara Widjanarko et al. 3 citations

Objectives: This secondary analysis examined five facets of mindful awareness as potential moderators of clinical outcomes using data from a randomized controlled trial (RCT) that compared Mantram Repetition Program (MRP) with present-centered therapy (PCT) in veterans with post-traumatic stress disorder (PTSD). Methods: Data were examined from 173 veterans with military-related PTSD randomly...

Ketamine alleviates PTSD-like effect and improves hippocampal synaptic plasticity via regulation of GSK-3β/GR signaling of rats.

Journal of Psychiatric Research October 1, 2024 Zixun Wang, Xinyu Hu, Zhongyi Wang et al. 9 citations

Each year, 3-4% of the global population experiences post-traumatic stress disorder (PTSD), a chronic mental disorder with significant social and economic repercussions. Although it has been shown that ketamine can effectively alleviate PTSD symptoms in individuals, the specific mechanism of action underlying its anti-PTSD effects remains unclear. In this study, we investigated how a single,...

Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial.

Contemporary Clinical Trials Communications October 1, 2024 Erica Eaton, Christy Capone, Brian J Gully et al. 2 citations

Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur and are associated with more severe symptomatology than either disorder alone, increased risk of suicide, and poorer response to existing treatments. A promising therapeutic intervention is the integration of 3,4-methylenedioxymethamphetamine (MDMA) and psychotherapy. The Food and Drug Administration (FDA)...

MDMA for treatment of PTSD and neurorehabilitation in military populations

Neurorehabilitation September 27, 2024 Walter Dunn, Anya K. Bershad, David E. Krantz et al. 2 citations

BACKGROUND: Neurorehabilitation in military populations is complicated by higher rates of PTSD and unique characteristics of military institutions. These factors can adversely impact the patient-therapist therapeutic alliance and engagement with the rehabilitation process leading to poorer outcomes. MDMA is a non-classical psychedelic with pro-social and fear regulating properties....

DOI: 10.3233/nre-230270 (opens in new tab) Full text (opens in new tab) MDMA Neurorehabilitation Alliance Psychotherapist +1

Ketamine ameliorates post-traumatic social avoidance by erasing the traumatic memory encoded in VTA-innervated BLA engram cells.

Neuron September 25, 2024 Ming Li, Xue-Ke Yang, Jian Yang et al. 30 citations

Erasing traumatic memory during memory reconsolidation is a promising retrieval-extinction strategy for post-traumatic stress disorder (PTSD). Here, we developed an acute social defeat stress (SDS) mouse model with short-term and re-exposure-evoked long-term social avoidance. SDS-associated traumatic memories were identified to be stored in basolateral amygdala (BLA) engram cells. A single...

Group Dissociation-Focused Cognitive Behavioral Therapy (DF-CBT) in Patients Suffering from a Dissociative Subtype of PTSD: An Exploratory Study

Journal of Trauma & Dissociation September 24, 2024 A. Vancappel, Claudie Chavigny, Lyna Chami et al.

ABSTRACT Dissociation is a widespread difficulty among patients suffering from Posttraumatic Stress Disorder (PTSD). However, there is no gold standard treatment for dissociative symptoms. Recent studies propose a cognitive and behavioral conceptualization for dissociation. The aim of this study was to explore the efficacy of a group program of Dissociation-Focused Cognitive Behavior Therapy...

Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents

Neuroscience & Biobehavioral Reviews September 20, 2024 Isabel Werle, Leandro J Bertoglio 17 citations

Threatening events and stressful experiences can lead to maladaptive memories and related behaviors. Existing treatments often fail to address these issues linked to anxiety/stress-related disorders effectively. This review identifies dose ranges associated with specific actions across various psychedelics. We examined psilocybin/psilocin, lysergic acid diethylamide (LSD),...

Beyond Pharmacology: A Narrative Review of Alternative Therapies for Anxiety Disorders.

Diseases September 16, 2024 Zuzanna Antos, Klaudia Zackiewicz, Natalia Tomaszek et al. 9 citations

Anxiety disorders significantly reduce patients' quality of life. Current pharmacological treatments, primarily benzodiazepines and antidepressants, are associated with numerous side effects. Consequently, there is a continual search for alternative methods to traditional therapies that are less burdensome for patients and broaden their therapeutic options. Our objective was to determine the...

Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging

medRxiv Preprint Server September 10, 2024 Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al. 4 citations preprint

Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine’s effects on...

Dramatic and persistent relief from chronic suicidality, emotional disturbances, and trauma symptomatology with oral ketamine and memantine in refractory depression with complex PTSD

Indian Journal of Psychiatry September 1, 2024 Harsimar Kaur, Chittaranjan Andrade 3 citations

Dear Editor, Ketamine is used off-label for indications ranging from depression to chronic pain. We know of no report of the successful use of oral ketamine, administered without psychotherapy, for complex posttraumatic stress disorder (cPTSD).[1,2] We describe a patient with chronic depression and cPTSD who failed >30 previous interventions but had dramatic and persistent relief from chronic...

The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.

Psychiatry Research September 1, 2024 Jianhua Yang, Ni Wang, Wulin Luo et al. 14 citations

3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is one of the most widely used illicit substances worldwide. MDMA-assisted psychotherapy has become a novel treatment for posttraumatic stress disorder (PTSD), and many randomized controlled trials (RCTs) have been performed over the past decade. Therefore, this study aimed to systematically review and demonstrate the efficacy...

Much anticipated FDA decision about psychedelics for PTSD ends with denial

Mental Health Weekly August 19, 2024 Valerie A. Canady

In a closely watched decision involving the use of psychedelic treatment and therapy to treat post‐traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)‐assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA‐assisted therapy to its drug maker, Lykos Therapeutics.

Combined Effects of Nasal Ketamine and Trauma-Focused Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder: A Pilot Case Series.

Behavioral Sciences August 16, 2024 Judith Rohde, Elena Hickmann, Marco Buchmann et al. 7 citations

This pilot case series investigated the feasibility and efficacy of an eight-week therapy program, combining nasally administered ketamine (0.5 mg/kg) with trauma-focused psychotherapy, for individuals with chronic, treatment-resistant post-traumatic stress disorder (PTSD). Three patients with chronic, treatment-resistant PTSD underwent the eight-week therapy program. Clinical assessments...

DOI: 10.3390/bs14080717 (opens in new tab) Full text (opens in new tab) Ketamine assisted Trauma focused PTSD-Treatment Ketamine-therapy +3

Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol.

Contemporary Clinical Trials August 1, 2024 Paulo R Shiroma, Paul Thuras, Melissa A Polusny et al. 7 citations

The 2023 VA/DoD Clinical Practice Guideline for the Management of PTSD recommends individual, manualized trauma-focused such as Prolonged Exposure (PE) over pharmacologic interventions for the primary treatment of PTSD. Unfortunately, clinical trials of trauma-based therapies in the military and veteran population showed that 30% to 50% of patients did not demonstrate clinically meaningful...

DOI: 10.1016/j.cct.2024.107569 (opens in new tab) Full text (opens in new tab) Prolonged exposure PTSD-Treatment Veterans-mental-health Ketamine-therapy +2

MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study.

Contemporary Clinical Trials Communications August 1, 2024 Leslie A. Morland, Dimitri Perivoliotis, Tamara R Wachsman et al. 4 citations

Posttraumatic Stress Disorder (PTSD) impacts both individual and relational functioning. Veteran couples are at increased risk of relationship distress due to military stressors such as deployment, family reintegration, and traumatic stress. Although both Cognitive-Behavioral Conjoint Therapy (CBCT) and its brief version (bCBCT) consistently have large effects on reducing PTSD symptoms, these...

DOI: 10.1016/j.conctc.2024.101314 (opens in new tab) Full text (opens in new tab) MDMA Intimate relationships PTSD Treatment Couples therapy +3